{"product_id":"codx-bcg-matrix","title":"(CODX) Co-Diagnostics, Inc. BCG Matrix Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock Strategic Clarity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Co-Diagnostics, Inc. BCG Matrix helps you quickly see how the company’s products or business units may fit into the four classic quadrants: Stars, Cash Cows, Question Marks, and Dogs. It is used for strategy, portfolio review, and decision-making, and this page already shows a real preview of the analysis, not just promotional text. Purchase the full version to get the complete ready-to-use report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eStars\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-Dx PCR platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Dx PCR is Co-Diagnostics, Inc.’s core growth engine for PCR testing, aimed at decentralized clinical labs and point-of-care use. The global PCR diagnostics market was about $7.4 billion in 2024 and is still growing, so this channel has room to scale. If adoption rises, Co-Dx PCR could become the company’s main share winner.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePortable PCR reader\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe portable PCR reader is a Star because it lets Co-Diagnostics, Inc. test outside centralized labs and fits the shift toward point-of-care care. Portable diagnostics are still a fast-growing category, with global molecular diagnostics demand rising as patients move closer to treatment sites. That wider use case makes the platform more flexible and raises the chance of repeat cartridge and assay sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePoint-of-care PCR\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePoint-of-care PCR is a Star for Co-Diagnostics, Inc. because rapid molecular tests cut turnaround time from days to minutes and fit clinic and urgent-care workflows. The global point-of-care diagnostics market was valued in the tens of billions in 2025 and is still expanding fast, backed by demand for faster infectious-disease answers. Co-Diagnostics, Inc. can use this segment to win visible placements and create repeat customer pull.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHome-use PCR testing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHome-use PCR testing is a Star for Co-Diagnostics, Inc. because it targets a faster-growing use case than routine lab testing and can widen access beyond hospitals and centralized labs. The upside is strong if Co-Diagnostics, Inc. can prove simple use, low cost, and clean regulatory execution.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher growth than standard lab PCR\u003c\/li\u003e\n\u003cli\u003eReaches home and retail buyers\u003c\/li\u003e\n\u003cli\u003eNeeds easy use, price control, approvals\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRespiratory multiplex panels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRespiratory multiplex panels fit Co-Diagnostics, Inc. as a Star because flu and COVID-19 testing stay seasonal but persistent, and one multiplex run can detect 2+ pathogens in a single sample. WHO still estimates seasonal influenza causes 3-5 million severe cases each year, so placements can turn into repeat reagent demand if hospitals and labs standardize on the panel.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher value than single-target tests\u003c\/li\u003e\n\u003cli\u003eBuilt for flu and COVID monitoring\u003c\/li\u003e\n\u003cli\u003eScales with placements and reorder rates\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe upside is execution-driven: if Co-Diagnostics wins menu spots, each installed instrument can support ongoing test volume instead of one-off sales.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-Dx PCR Powers Co-Diagnostics’ Growth Runway\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc.’s Stars are the platforms tied to fast-growing PCR demand, especially Co-Dx PCR, portable readers, point-of-care use, and home testing. The PCR diagnostics market was about $7.4 billion in 2024, and point-of-care diagnostics was valued in the tens of billions in 2025, so the growth runway is still open.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStar\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCo-Dx PCR\u003c\/td\u003e\n\u003ctd\u003eCore growth engine\u003c\/td\u003e\n\u003ctd\u003e$7.4B PCR market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePoint-of-care PCR\u003c\/td\u003e\n\u003ctd\u003eFast turnaround\u003c\/td\u003e\n\u003ctd\u003eTens of billions in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome-use PCR\u003c\/td\u003e\n\u003ctd\u003eBroader access\u003c\/td\u003e\n\u003ctd\u003eHigher-growth use case\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCo-Diagnostics’ BCG Matrix maps its diagnostic products by growth and share, showing where to invest, hold, or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOne-page BCG Matrix for Co-Diagnostics, Inc. to quickly pinpoint growth, cash, and drag areas.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a clear source trail for Co-Diagnostics, Inc., boosting credibility and helping decision-makers verify key claims fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCash Cows\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized reagents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSpecialized reagents are Co-Diagnostics, Inc.'s closest thing to a steady cash engine because customers must reorder them for repeat testing, not just buy them once. That makes revenue less tied to new product launches and more linked to installed testing volume. In BCG terms, this is the part of the portfolio that can keep generating cash even when new assay demand is uneven.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCoPrimer IP\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCoPrimer IP is a repeatable assay-design asset, so one proprietary platform can support many test builds. That makes it a lower-growth Cash Cow than new launches, but it can still lift gross margin and cut development cost. For Co-Diagnostics, that steady IP value helps fund the rest of the pipeline.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOEM reagent supply\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOEM reagent supply fits a cash cow profile because once Company Name locks in supply agreements, orders can recur with little extra selling spend. That cuts commercial friction and supports steadier cash flow than early-stage product development, which burns cash on R\u0026amp;D and launch costs. Co-Diagnostics, Inc. can use this channel to harvest margin from installed relationships while keeping marketing outlays lean.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eInstalled assay consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInstalled assay consumables fit the Cash Cows box because repeat purchases from the installed base can keep coming after the first assay sale. For Co-Diagnostics, Inc., that matters most when new assay launches are slower, since consumables need less selling work and can help smooth cash flow.\u003c\/p\u003e\n\u003cp\u003eRecent filings show Co-Diagnostics, Inc. still operates at a very small revenue scale, so even modest repeat consumable demand can matter more than a one-off instrument sale. The best case is a base of recurring orders with low extra SG\u0026amp;A, which supports gross-margin stability.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepeat revenue after first sale\u003c\/li\u003e\n\u003cli\u003eLower sales effort than new assays\u003c\/li\u003e\n\u003cli\u003eHelps smooth cash flow\u003c\/li\u003e\n\u003cli\u003eBest when installed base grows\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eResearch-use molecular components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eResearch-use molecular components at Co-Diagnostics, Inc. fit the Cash Cows bucket because RUO products are mature, low-growth, and can keep producing repeat revenue without heavy consumer marketing. That matters while larger bets mature, since the company can lean on recurring component sales to offset weak demand in newer lines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRUO: mature, low-growth revenue\u003c\/li\u003e\n\u003cli\u003eLower marketing spend than consumer products\u003c\/li\u003e\n\u003cli\u003eSupports cash flow while newer bets mature\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-Diagnostics Cash Cows: Reorders Driving Steady Cash Flow\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCash Cows at Co-Diagnostics, Inc. are the repeat-buy lines: reagents, OEM supply, installed consumables, and RUO molecular components. These are the best fit for steady cash because they rely on reorders, not new launch spend, so they can help fund the rest of the portfolio.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCash Cow\u003c\/th\u003e\n\u003cth\u003eWhy it fits\u003c\/th\u003e\n\u003cth\u003e2025\/2026 value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eReagents\u003c\/td\u003e\n\u003ctd\u003eRepeat testing demand\u003c\/td\u003e\n\u003ctd\u003eRecurring revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOEM supply\u003c\/td\u003e\n\u003ctd\u003eContract reorders\u003c\/td\u003e\n\u003ctd\u003eLow selling cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003eInstalled-base sales\u003c\/td\u003e\n\u003ctd\u003eStable cash flow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Version Awaits\u003c\/span\u003e\u003cbr\u003eCo-Diagnostics, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThe Co-Diagnostics, Inc. BCG Matrix preview you’re viewing is the exact same document you’ll receive after purchase. No demo content or placeholders—just the full, ready-to-use strategic analysis. Once purchased, the file is instantly available for download, editing, printing, or sharing with your team.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDogs\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy SARS-CoV-2 assay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc.'s legacy SARS-CoV-2 assay fits Dogs: COVID-19 testing has shrunk sharply from its 2020-2021 peak, and the market is now crowded with low-priced rivals. In Co-Diagnostics, Inc.'s latest reported results, COVID-related revenue was minimal versus its peak, while total revenue remained only a few million dollars. That makes this assay a weak growth driver and more of a hold-or-exit asset.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHPV assay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHPV testing is a mature, crowded market: WHO says HPV drives about 99% of cervical cancer, and giants like Roche, Hologic, and Abbott already control broad distribution. For Co-Diagnostics, Inc., that makes the HPV assay a Dogs asset in the BCG Matrix, with weak share gains unless it can scale fast and win channel access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHepatitis B assay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHepatitis B assay fits the Dogs side of Co-Diagnostics, Inc.’s BCG Matrix because it sits in a mature 2025 diagnostics market where Abbott, Roche, and Thermo Fisher already dominate hospital and lab channels. With hepatitis B still affecting about 254 million people worldwide, demand is steady, but standalone growth is limited and price pressure is high. Co-Diagnostics is unlikely to build enough share here to reach star status, and without scale it also looks too small to be a true cash cow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHepatitis C assay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eHepatitis C assay fits Co-Diagnostics, Inc. Dogs because the market is mature, crowded, and price-driven. WHO still estimates about 50 million people live with chronic HCV and roughly 1.0 million new infections occur each year, but most demand is in established lab channels, not fast-growing decentralized testing. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow-share legacy assay\u003c\/li\u003e\n\u003cli\u003eLimited growth vs newer tests\u003c\/li\u003e\n\u003cli\u003eNot a priority asset\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThat makes it look more like a maintenance product than a growth engine for Co-Diagnostics, Inc. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLow-volume single-target assays\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc.’s low-volume single-target assays sit in the \"Dogs\" bucket because single-analyte tests face tight pricing and weak differentiation, so small-scale production struggles to cover fixed costs. That makes them the most likely cash traps if demand stays thin, especially in a market where higher-throughput PCR and multiplex panels keep taking share. In FY2025, the key risk is not growth but whether these assays can earn enough margin to avoid dragging cash flow lower.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHeavy price pressure\u003c\/li\u003e\n\u003cli\u003eWeak scale economics\u003c\/li\u003e\n\u003cli\u003eLow differentiation\u003c\/li\u003e\n\u003cli\u003eHigh cash-trap risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCo-Diagnostics’ Legacy Assays Are Stuck in Low-Growth, High-Pressure Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc.'s Dogs are low-share, low-growth assays with weak pricing power and high cash-trap risk. COVID revenue has faded from its 2020-2021 peak, so the legacy SARS-CoV-2 test is no longer a growth driver. HPV, HBV, HCV, and single-target assays also sit in crowded 2025 markets where scale leaders control channels.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAssay\u003c\/th\u003e\n\u003cth\u003eDog signal\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eHPV\u003c\/td\u003e\n\u003ctd\u003eMature market\u003c\/td\u003e\n\u003ctd\u003e~99% of cervical cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHBV\u003c\/td\u003e\n\u003ctd\u003ePrice pressure\u003c\/td\u003e\n\u003ctd\u003e~254M people affected\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHCV\u003c\/td\u003e\n\u003ctd\u003eLimited growth\u003c\/td\u003e\n\u003ctd\u003e~50M chronic cases; ~1.0M new\/year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eQuestion Marks\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTB assay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWHO estimated 10.8 million TB cases and 1.25 million deaths in 2023, so the need for better diagnostics is still huge. Co-Diagnostics, Inc.'s TB assay sits in a growing global health niche, but it does not show dominant market share. That makes it a classic Question Mark: high need, uncertain share, and a clear invest-or-exit call.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMalaria assay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc.’s malaria assay sits in a Question Mark spot: global demand is real, with WHO reporting 263 million malaria cases and 597,000 deaths in 2023, mostly in Africa. But share is hard to win without strong local distribution and public-sector access, so the product needs a clear commercial push. Without that, it can stay small instead of moving toward a Star.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChikungunya assay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eChikungunya is a niche but relevant assay: WHO says about 5.6 billion people live in areas at risk, across more than 110 countries. For Co-Diagnostics, Inc., growth can come from outbreak detection and surveillance, but the product still needs broader adoption to move beyond Question Mark status. Until public-health buying becomes repeatable, it stays a low-share, high-uncertainty bet.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eDengue assay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc.’s dengue assay fits a Question Mark: dengue is a major need in tropical markets, with WHO estimating 100 to 400 million infections a year, and climate spread plus travel testing can widen demand. But Co-Diagnostics, Inc. still lacks enough share and scale to call it a cash cow, so returns depend on adoption in endemic countries and at ports of entry.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDengue demand is large and recurring.\u003c\/li\u003e\n\u003cli\u003eClimate spread can lift future testing.\u003c\/li\u003e\n\u003cli\u003eCurrent share still looks too small.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMosquito pathogen tests\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMosquito pathogen tests fit Co-Diagnostics, Inc.'s PCR-based detection strength, but they are still a question mark because commercial scale is unproven. The business has not shown that vector-screening can move beyond niche demand, so the upside is real but the share of value is still low and speculative.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrong tech fit\u003c\/li\u003e\n\u003cli\u003eWeak scale proof\u003c\/li\u003e\n\u003cli\u003eHigh upside, low share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHuge Disease Markets, But Co-Diagnostics’ Scale Is Still Unproven\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCo-Diagnostics, Inc.’s TB, malaria, chikungunya, dengue, and mosquito pathogen assays are Question Marks: demand is large, but share is still unclear. WHO put TB at 10.8 million cases in 2023, malaria at 263 million, and dengue at 100-400 million infections a year. The upside is real, but scale is not proven yet.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAssay\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003cth\u003eNeed\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTB\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003e10.8M cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMalaria\u003c\/td\u003e\n\u003ctd\u003eQuestion Mark\u003c\/td\u003e\n\u003ctd\u003e263M cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234230804745,"sku":"codx-bcg-matrix","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/codx-bcg-matrix.webp?v=1785715470","url":"https:\/\/dcfanalyst.com\/products\/codx-bcg-matrix","provider":"DCF Analyst","version":"1.0","type":"link"}